- Location
rivaroxaban
"-
Bayer HealthCare Has Failed to Win The Backing of The US FDA's Cardiovascular
Jan 20, 2014Bayer HealthCare has failed to win the backing of the US FDA's Cardiovascular and Renal Drugs Advisory Committee to expand the use of its oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily (BID) in combination with standard ...
Tags: FDA Panel, ACS Patients
-
Janssen Research & Development Has Submitted Supplemental New Drug Applications
Dec 5, 2012Janssen Research & Development has submitted supplemental New Drug Applications (sNDAs) to the US Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban), an oral anticoagulant. Janssen said the drug is used to treat ...
Tags: Xarelto, rivaroxaban, DVT, pulmonary embolism, VTE
-
Janssen Research & Development Has Submitted a Supplemental New Drug Application
Dec 3, 2012Janssen Research & Development has submitted a supplemental new drug application (sNDA) with FDA, seeking approval to use Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with acute coronary ...
-
Bayer Oral Anticoagulant Xarelto Has Gained Positive CDR Recommendation
Nov 28, 2012Bayer oral anticoagulant Xarelto has gained positive common drug review (CDR) recommendation from the Canadian Agency for Drugs and Technologies in Health for the prevention of stroke and systemic embolism in atrial fibrillation (AF) ...
Tags: Bayer oral anticoagulant Xarelto, CDR Recommendation, Stroke Prevention
Related Products
-
Wholesale Antibiotic Pharmaceutical Intermediate Rivaroxaban Powder CAS 366789-02-8
-
Factory Supplier Hot Selling High Purity Rivaroxaban CAS 366789-02-8
-
High Quality Rivaroxaban 99.8% Purity CAS 366789-02-8 with Good Price
-
Hot American Products in Stock High Quality CAS 366789-02-8 Rivaroxaban
-
API Rivaroxaban 366789-02-8
-
Rivaroxaban 366789-02-8 High Quality and Competitive Price
